Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses

Visual Acuity Clinical Trial

Official title:

Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04529109
• Other study ID #: CR-6395
• Status: Completed
• Phase: N/A
• Start date: August 13, 2020
• Est. completion date: September 15, 2020

Study information

• Verified date: October 2021
• Source: Johnson & Johnson Vision Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a randomized, double-masked, bilateral, cross-over, 2 treatment by 2 period dispensing study. There will be 4 visits. There will be a 2 to 5 day washout period between treatments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: September 15, 2020
• Est. primary completion date: September 15, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 29 Years

Eligibility

Inclusion Criteria:

-Potential subjects must satisfy all of the following criteria to be enrolled in the study:

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form

2. Females between 18 and 29 (inclusive) years of age at the time of screening

3. Appear able and willing to adhere to the instructions set forth in this clinical protocol (i.e. willing to wear only the study lenses and not use habitual lenses during the dispensing periods)

4. Be a current soft contact lens wearer in both eyes with a minimum of 6 hours/day and 5 days/week over the last month by self-report

5. Be a current wearer of cosmetic/circle lenses in the last 6 months, by self-report.

6. The subject must be willing to be photographed and/or video-taped

7. The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 D to -6.00 D (inclusive) in each eye

8. The subject's refractive cylinder must be less than or equal to 0.75 D (inclusive) in each eye

9. Have spherical best corrected visual acuity of 20/25 or better in each eye.

Exclusion Criteria:

1. Currently pregnant or lactating

2. Any systemic disease (eg, Sjögren's Syndrome), allergies, infectious disease (eg, hepatitis, tuberculosis), contagious immunosuppressive diseases (eg, HIV), autoimmune disease (eg, rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study (at the investigators discretion)

3. Use of systemic medications (eg, chronic steroid use) that are known to interfere with contact lens wear (at the investigators discretion)

4. Any previous or planned (during the study) ocular surgery (eg, radial keratotomy, PRK, LASIK, etc.).

5. Any previous history or signs of a contact lens-related corneal inflammatory event (eg, past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear (at the investigators discretion).

6. Participation in any contact lens or lens care product clinical trial within seven (7) days prior to study enrollment

7. Employee or family members of clinical site (eg, Investigator, Coordinator, Technician)

8. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion (at the investigators discretion)

9. Clinically significant (Grade 3 or 4 on FDA scale) tarsal abnormalities, bulbar injection, corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.

Related Conditions & MeSH terms

• Visual Acuity

Intervention

Device:
• etafilcon A investigational cosmetic lens 1
TEST
• etafilcon A investigational cosmetic lens 2
CONTROL

Locations

Country	Name	City	State
Hong Kong	Vital Eyecare Center	Mongkok	Kowloon
Hong Kong	Sight Enhancement Center	Yau Ma Tei	Kowloon
United States	Stam & Associates Eye Care	Jacksonville	Florida
United States	Frazier Vision, Inc	Tyler	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Vision Care, Inc.

Countries where clinical trial is conducted

United States,  Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Eyes With Distance Monocular Visual Acuity (logMAR) Lower Than 0.176 logMAR	Visual acuity on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. However, the data was dichotomized as Y=1 if logMAR visual acuity was less than 0.176 logMAR; and Y=0 otherwise. A value of 0.176 logMAR ?20/30 Snellen Visual Acuity. The proportion of eyes with visual acuity lower than 0.176 logMAR was reported.	5- Minutes Post-Lens Fitting